ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA - Business Wire

ImmunityBio is advancing regulatory discussions with the FDA regarding a potential resubmission path for its product ANKTIVA. The stock surged 26% following the FDA's outline of this resubmission path. Additionally, the Saudi FDA has approved ANKTIVA for bladder and lung cancer. This biotech stock has increased more than 100% this year.